Centrose, LLC

Madison, WI 53717

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $1.54MM
First Award Date 07/15/07
Most Recent Award Date 05/01/14

Key Personnel

Last Name Name Awards Contact
Hutchinson Charles R Hutchinson 6 Message
Prudent James R. Prudent 3 Message

9 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 05/01/14 - 10/31/14

Project Summary The incidence of renal cell cancer has been rising steadily and for those that have tumor recurrence after surgery, the prognosis is generally poor. In 2013 an estimated 65,150 new cases and 13,680 deaths will be attributed to renal cancer in the United States. Renal cancer is the most common malignancy of the adult kidney and ac...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 09/09/11 - 03/08/12

DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) is among the most common and lethal cancers yet, the current standard of care for advanced stage NSCLC provides only modest improvements in overall survival or quality of life. Thus, there exists a significant unmet need for new effective therapies to treat NSCLC. Herein we...

Phase 1 SBIR

Agency: National Science Foundation
Topic: BC-2010
Budget: 01/01/11 - 12/31/11

This Small Business Innovation Research Phase I project highlights a strategy for the development of the first integrated high throughput pipeline to synthesize and evaluate novel sugar-drug conjugates. The core innovation of this proposed phase I study is an enzyme catalyzed one-step glycosylation reaction that also presents a convenient colori...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 07/14/09 - 10/31/09

DESCRIPTION (provided by applicant): Current antifungal therapy is limited by the types of drugs available to treat systemic infections due to emerging and comparatively rare fungi different from the common strains of pathogenic Candida, Aspergillus, Cryptococcus and the Zygomycoses. Neutropenic and immunocompromised patients, such as those with...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 04/01/09 - 03/31/11

DESCRIPTION (provided by applicant): Current antifungal therapy is limited by the types of drugs available to treat systemic infections due to emerging and comparatively rare fungi different from the common strains of pathogenic Candida, Aspergillus, Cryptococcus and the Zygomycoses. Neutropenic and immunocompromised patients, such as those with...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-13
Budget: 02/01/08 - 01/31/10

DESCRIPTION (provided by applicant): The process of small molecule and natural product glycorandomization developed by Thorson and coworkers has been validated as one of the first simple, efficient and general glycosylation strategies for small molecule and macromolecular therapeutics. Given its broad utility and documented impact on improving t...

Phase 1 STTR

Institution: University of Wisconsin, Madison

Agency: National Science Foundation
Topic: 2008
Budget: 01/01/08 - 12/31/08

This Small Business Technology Transfer Research Phase I project develops methodology needed for the production of sugar enhanced (glycosidic) compound libraries and final therapeutic leads. Sugar attachments have been identified as a powerful way to make therapeutically relevant small molecules. Examples of drugs with sugar attachments such as ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 09/27/07 - 08/31/09

DESCRIPTION (provided by applicant): Epidemiological evidence points to the value of cardiac glycosides like digoxin and digitoxin for treatment of breast cancer and recent reports suggest they may be especially useful to treat non-small cell lung cancer. These and other findings underlie our belief that a cancer drug could be developed from suc...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 07/15/07 - 06/30/09

DESCRIPTION (provided by applicant): Although it has long been known that macrolide glycosylation is absolutely essential for antibacterial activity, the megalomicins (which differ from erythromycins solely via an additional sugar attached at C6 of the macrolide) were the first macrolides to display notable antiviral and antiparasitic activities...